Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, is
proud to be a part of the Blueprint PD-L1 Assay Comparison Project, an
important initiative to compare several new diagnostic tests for the
immune biomarker PD-L1 in non-small cell lung cancer (NSCLC).
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more